%PDF-1.4
%
38 0 obj
<>
endobj
35 0 obj
<>
endobj
96 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-10T11:29:27Z
2024-03-28T01:33:29-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T01:33:29-07:00
application/pdf
Heather
2002-481.suppl.65
uuid:b6c61e30-1dd1-11b2-0a00-400827bd3700
uuid:b6c61e33-1dd1-11b2-0a00-5b0000000000
endstream
endobj
24 0 obj
<>
endobj
25 0 obj
<>
endobj
39 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
20 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
114 0 obj
[118 0 R]
endobj
115 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
54 54 m
558 54 l
S
BT
/CS0 cs 0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 354.2144 35.9844 Tm
[(The Journal of Rheumatology 2002, V)110.8 (olume 29, Supplement 65)]TJ
0 Tw -37.5268 -0.0313 Td
(26)Tj
ET
0 0 0 0 scn
/GS0 gs
103.25 59.75 407.5 -10.83 re
f*
0.5 w
103.25 59.75 407.5 -10.83 re
S
BT
0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
-0.0002 Tc 10 0 0 10 54 713.1616 Tm
(CONCLUSION)Tj
/TT2 1 Tf
-0.00011 Tc 0.1212 Tw 0 -1.2 TD
[(The results from clinical trials show that tar)17.7 (geting )17.8 (TNF-)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 23.3691 0 Td
(\002)Tj
/TT2 1 Tf
0.00571 Tw -23.3691 -1.2 Td
(and IL-1 can relieve the signs and symptoms of RA, as well)Tj
0.00591 Tw T*
[(as delay the progression of joint damage. )17.8 (While tempting, it)]TJ
0.1273 Tw T*
[(is dif)17.8 (ficult to compare the ef)17.8 (ficacy of the )17.7 (TNF-)]TJ
/T1_0 1 Tf
0 Tw 19.7896 0 Td
(\002)Tj
/TT2 1 Tf
1.0083 0 Td
[(tar)17.8 (geted)]TJ
0.01089 Tc 0.364 Tw -20.7979 -1.2 Td
[(therapies with anakinra because of dif)17.8 (ferences across)]TJ
0 Tc 0.1077 Tw T*
(studies in patient populations, study designs, and outcome)Tj
-0.0298 Tw T*
[(measures. Rather than focusing on their relative ef)17.8 (ficacy)65 (, the)]TJ
0.355 Tw T*
(challenge now is to develop a means to individualize)Tj
0.136 Tw T*
(therapy for optimal clinical response. Can patient-specific)Tj
0.116 Tw T*
(tests, such as the identification of genetic polymorphisms,)Tj
0.1767 Tw T*
[(be developed to predict the response to )17.8 (TNF-)]TJ
/T1_0 1 Tf
0 Tw 19.2955 0 Td
(\002)Tj
/TT2 1 Tf
-0.00011 Tc 0.1767 Tw 1.0576 0 Td
(and IL-1)Tj
0 Tc 0.1429 Tw -20.3531 -1.2 Td
[(inhibitor therapy? )17.7 (What are the advantages and disadvan-)]TJ
0.1519 Tw T*
[(tages of combining a )17.8 (TNF-)]TJ
/T1_0 1 Tf
0 Tw 11.4196 0 Td
(\002)Tj
/TT2 1 Tf
0.1519 Tw 1.0328 0 Td
(and an IL-1 antagonist? Do)Tj
0.19569 Tw -12.4524 -1.2 Td
(these cytokine antagonists prevent joint destruction inde-)Tj
0.0674 Tw T*
[(pendent of their antiinflammatory ef)17.8 (fects? )17.8 (W)79.8 (orking toward)]TJ
0.02161 Tw T*
(the answers to these questions will likely improve longterm)Tj
0.02499 Tw T*
(outcomes and lead to innovative treatment strategies.)Tj
/TT1 1 Tf
-0.00011 Tc 0 Tw 0 -2.2 TD
(REFERENCES)Tj
/TT2 1 Tf
0.02499 Tw 8 0 0 8 61 477.1616 Tm
[(1.)-625.1 (Moreland L)73.9 (W)91.7 (, Schif)17.7 (f MH, Baumgartner SW)91.7 (, et al. Etanercept)]TJ
0 Tc 1.375 -1.25 Td
[(therapy in rheumatoid arthritis. )54.9 (Ann Intern Med 1990;130:478-86.)]TJ
-0.00011 Tc -1.375 -1.25 Td
[(2.)-625.1 (W)79.7 (einblatt ME, Kremer JM, Bankhurst )54.8 (AD, et al. )54.8 (A)-219.9 (trial of)]TJ
0 Tc 1.375 -1.25 Td
(etanercept, a recombinant tumor necrosis factor receptor:Fc fusion)Tj
0 -1.25 TD
(protein, in patients with rheumatoid arthritis receiving methotrexate.)Tj
T*
(N Engl J Med 1999;340:253-9.)Tj
-0.00011 Tc -1.375 -1.25 Td
[(3.)-625.1 (Bathon JM, Martin R)54.8 (W)91.7 (, Fleischmann RM, et al. )54.8 (A)-219.9 (comparison of)]TJ
0 Tc 1.375 -1.25 Td
(etanercept and methotrexate in patients with early rheumatoid)Tj
T*
(arthritis. N Engl J Med 2000;343:1586-93.)Tj
31.625 39.671 Td
[(4.)-625 (Maini RN, Breedveld FC, Kalden JR, et al. )17.7 (Therapeutic ef)17.8 (ficacy of)]TJ
-0.00011 Tc 1.375 -1.25 Td
(multiple infusions of anti-tumor necrosis factor )Tj
/T1_0 1 Tf
0 Tc 0 Tw [-0.2 (\002)]TJ
/TT2 1 Tf
20.2158 0 Td
(monoclonal)Tj
0.02499 Tw -20.2158 -1.25 Td
(antibody combined with low-dose methotrexate therapy in )Tj
T*
[(rheumatoid arthritis. )54.9 (Arthritis Rheum 1998;41:1552-63.)]TJ
-1.375 -1.25 Td
[(5.)-625 (Maini RN, St.Clair EW)91.8 (, Breedveld F)79.8 (, et al. Infliximab \(chimeric)]TJ
-0.00011 Tc 1.375 -1.25 Td
(anti-tumour necrosis factor )Tj
/T1_0 1 Tf
0 Tc 0 Tw [0.1 (\002)]TJ
/TT2 1 Tf
0.02499 Tw 12.0588 0 Td
(monoclonal antibody\) vs placebo in)Tj
-12.0587 -1.25 Td
(rheumatoid arthritis patients receiving concomitant methotrexate: a)Tj
T*
(randomized phase III trial. Lancet 1999;354:1932-9.)Tj
-1.375 -1.25 Td
[(6.)-625 (Lipsky PE, van der Heijde DM, St.Clair EW)91.8 (, et al. Infliximab and)]TJ
1.375 -1.25 Td
(methotrexate in the treatment of rheumatoid arthritis. N Engl J Med)Tj
0 Tw T*
(2000;343:1594-602.)Tj
-0.00011 Tc 0.02499 Tw -1.375 -1.25 Td
[(7.)-625.1 (Bresnihan B, )54.8 (Alvaro-Gracia JM, Cobby M, et al. )17.7 (T)34.8 (r)-0.1 (eatment of)]TJ
0 Tc 1.375 -1.25 Td
(rheumatoid arthritis with recombinant human interleukin-1 receptor)Tj
T*
[(antagonist. )54.9 (Arthritis Rheum 1998;41:2196-204. )]TJ
-1.375 -1.25 Td
[(8.)-625 (Cohen S, Hurd E, Cush J, et al. )17.8 (T)34.9 (reatment of rheumatoid arthritis)]TJ
1.375 -1.25 Td
(with anakinra, a recombinant human interleukin-1 receptor )Tj
T*
(antagonist, in combination with methotrexate. Results of a 24-week,)Tj
T*
[(multicenter)39.8 (, randomized, double-blind, placebo-controlled trial.)]TJ
T*
(Arthritis Rheum 2002;46:614-24.)Tj
0 Tw -1.375 -1.25 Td
[(9.)-625 (http://www)64.9 (.fda.gov/ohrms/dockets/ac/01/slides/3779s1_02_)]TJ
0.02499 Tw 1.375 -1.25 Td
[(CBER%20amgen/index.htm Biological Licence )54.9 (Application:)]TJ
T*
[(Anakinra for Rheumatoid )54.9 (Arthritis, )54.9 (Aug. 20, 2001.)]TJ
-0.00011 Tc -1.875 -1.25 Td
[(10.)-625.1 (V)111 (an der Heijde DM. Plain X-rays in rheumatoid arthritis: overview)]TJ
0 Tc 1.875 -1.25 Td
[(of scoring methods, their reliability and applicability)64.9 (. Baillieres Clin)]TJ
T*
(Rheumatol 1996;10:435-53.)Tj
-1.8381 -1.25 Td
[(1)36.9 (1.)-625 (Larsen )54.9 (A, Dale K, Eek M. Radiographic evaluation of rheumatoid)]TJ
1.8381 -1.25 Td
[(arthritis and related conditions by standard reference films. )54.9 (Acta)]TJ
T*
(Radiol Diagn 1977;18:481-91.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(12.)-625.1 (Sharp JT)73.9 (, Strand )17.7 (V)129.1 (, Leung H, Hurley F)79.7 (, Loew-Friedrich I. )17.7 (T)34.8 (reatment)]TJ
1.875 -1.25 Td
(with leflunomide slows radiographic progression of rheumatoid)Tj
0 Tc T*
[(arthritis. )54.9 (Arthritis Rheum 2000;43:495-505.)]TJ
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_1 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
43 0 obj
<>
endobj
85 0 obj
<>
endobj
101 0 obj
<>
endobj
42 0 obj
<>
endobj
58 0 obj
<>
endobj
45 0 obj
<>
endobj
44 0 obj
<>
endobj
78 0 obj
<>stream
HtV
pT}ow BBGb(l
K
0wMKtI(0 #-8NDh@AJK+82vBF-0v҂bݗ
t|{~sy@3s/MjiV
4|h._Verf}},[)䩅ϭX0nF^`Ni2\qpr,QGMHvcrߡ%?^Z˼Yyj~VYOY/ WQG-4mz&q=V y-dl8d?갓p O ٸ"7.I)oIh4ATaį!w@5}sxuQx-n@Je^Na/;>:F`==ڬ!7 d*v.V>`$! XǵІvџ0b.6U쀉?bحU9̠sDOq\[͖ų
^߅؇_Jpt7L1W3Vq5?wD<+ى2OlQ#֊qZhuc"L`H)3݂mx;wCNkmg8Yk&CSވIIb96e$>]}KT,.$dO9>֪IKwވ]Z۬3]V/b13cf|&V
p#&2XhQ 払78+Rȁv*vXlԝNV;xu%sgVGqg_q3m!&ƈq"yN1Eb13WubX'vv}*3h']7HJt4i,E,HFfI6
ZVIvBkڵwz^??o)aَ942~a׳]p=~5uc.r?c97Q'H$?i8 Dz2?zfhzԾ}ݫgJrR .CפРQY!S2&O)b
1=!wx{8
Iy3J)oe-O-܃
`Z$1E4E õ٬n
v!Q611\I#SA3~F^2
s`Q7ˍgLfvCגRH反+-~<RRRS29L5fkiS;.,W65'w!7Q+aX:s諸*Kc#PbQRz(ݟ42KִclJooci;/u?;hyQu1ir檯\4ҍ2*sL1<
w2nx[)wDu'qv"fc]GGHif#;(Z gbu1(KP6b>1z%E"yDJL
l%!F#fԻ棕d8 F++yC9Sk
y*νjlum\ў8ru<}ݮGeyplU^;(3/e[9F/ޓLCrϘ#v^q}cFΚT*_WA\"nvazQm/U~mٌJ9qZ]Vv?